Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study
Canada Communicable Disease Report · 20.11.2023 · 49 (10) · 440-445
DOI: 10.14745/ccdr.v49i10a05 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Canada Communicable Disease Report, online erschienen am 20.11.2023. Verfasst von Nadine Sicard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Agency of Canada, Infectious Disease Programs Branch, Montréal, QC. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Public Health Agency of Canada, Infectious Disease Programs Branch, Montréal, QC.
- Public Health Agency of Canada, Infectious Disease Programs Branch, Ottawa, ON.
- Public Heath Agency of Canada, Centre for Communicable Diseases and Infection Control, Ottawa, ON.
- Memorial University of Newfoundland, Faculty of Medicine, Division of Infectious Diseases, St. John's, NL.
Zitieren
APA
Sicard, N., Squires, S., Mullah, M., & Daley, P. (2023). Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study. Canada Communicable Disease Report, 49(10), 440-445. https://doi.org/10.14745/ccdr.v49i10a05
Vancouver
Sicard N, Squires S, Mullah M, Daley P. Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study. Canada Communicable Disease Report. 2023;49(10):440-445. doi:10.14745/ccdr.v49i10a05
BibTeX
@article{Sicard2023,
author = {Sicard, Nadine and Squires, Susan and Mullah, Muhammad and Daley, Peter},
title = {Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study},
journal = {Canada Communicable Disease Report},
year = {2023},
volume = {49},
number = {10},
pages = {440--445},
doi = {10.14745/ccdr.v49i10a05}
}
EUVIMED